title: Cognitive functions, epileptic syndromes and antiepileptic drugs.
abstract: Cognitive function of patients on monotherapy specific for their epileptic syndrome has been studied infrequently. We evaluated 7 patients with symptomatic localised epilepsies (SEL) on phenytoin aged 30 +/- 12 (mean +/- standard deviation) years, 8 with idiopathic generalised epilepsies on sodium valproate aged 18 +/- 4 years, 16 with SEL on carbamazepine aged 28 +/- 11 years, and 35 healthy controls aged 27 +/- 11 years. All subjects were of normal intelligence, educated appropriately to age, and led productive lives in the community. Two of the patients on carbamazepine and one on valproate had less than five partial, absence or myoclonic seizures monthly, the remaining were controlled. Carbamazepine serum concentrations were 12 +/- 5 micrograms/ml, phenytoin were 23 +/- 7, and valproate were 62 +/- 23 (mean +/- sd). Tests included immediate recall and recognition for pictures, Stroop test, delayed recall and recognition of pictures. Patients on phenytoin and valproate performed significantly worse than controls on immediate recall, and patients on carbamazepine performed significantly worse than controls in Stroop test (p < 0.01). The results indicate relatively minor effects of the epileptic syndromes and of phenytoin, carbamazepine and valproate on cognition of patients with controlled epilepsy leading productive lives in the community. We conclude that the cognitive deficit found in chronic epileptic patients on poly-therapeutic drug regimen must be multifactorial, and that future studies need to control for all possible variables in order to achieve meaningful results.
authors.affiliation: Clinical Neurology Unit, Hospital N. Sra. das Graças, Curitiba, Brasil.
authors.forename: P R
authors.initials: PR
authors.lastname: Bittencourt
authors.forename: M J
authors.initials: MJ
authors.lastname: Mader
authors.forename: M M
authors.initials: MM
authors.lastname: Bigarella
authors.forename: M P
authors.initials: MP
authors.lastname: Dóro
authors.forename: A M
authors.initials: AM
authors.lastname: Gorz
authors.forename: T M
authors.initials: TM
authors.lastname: Marcourakis
authors.forename: Z S
authors.initials: ZS
authors.lastname: Ferreira
mesh_terms: D000293:Adolescent; D000328:Adult; D002220:Carbamazepine / Q000097:blood / Q000627:therapeutic use; D002648:Child; D003071:Cognition / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000097:blood / Q000627:therapeutic use; D011446:Prospective Studies; D014635:Valproic Acid / Q000097:blood / Q000627:therapeutic use
chemical_list: D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin